Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287686 | 1.00 | CA1 (0.60) | CA1CA2CA12CA7CA14 | |
| SCHEMBL30065675 | 1.00 | CA1 (0.60) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3287766 | 1.00 | CA1 (0.60) | CA1CA2CA12CA7CA14 | |
| SCHEMBL13866065 | 1.00 | CA1 (0.60) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3287764 | 1.00 | CA1 (0.60) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3287692 | 1.00 | CA1 (0.60) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3293132 | 0.92 | FLT1 (0.53) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3293133 | 0.92 | FLT1 (0.53) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3293141 | 0.92 | FLT1 (0.53) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3292574 | 0.91 | CA1 (0.51) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | claimed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | claimed |
| EP-2207540-B1 | CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-7723391-B2 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093525-A1 | Cyclopropyl aryl amide derivatives and uses thereof | AR, ADRA2A, ADRA1A | CA1 3991/4885CA2 2746/4885CA12 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.